Engineered protein could reduce bleeding after heart attack, study finds

08/14/2014 | Science World Report

The investigational drug APT102 may reduce tissue damage and bleeding risk following a heart attack, according to a Washington University School of Medicine in St. Louis animal study in the journal Science Translational Medicine. The drug is an engineered version of the anti-inflammatory and anti-clotting protein apyrase.

View Full Article in:

Science World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD